Rv1985c，一种有前途的新型抗原，可用于诊断卡介苗接种对照者中的结核感染。
Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls.
机构信息
Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
出版信息
BMC Infect Dis. 2010 Sep 17;10:273. doi: 10.1186/1471-2334-10-273.
BACKGROUND
Antigens encoded in the region of difference (RD) of Mycobacterium tuberculosis constitute a potential source of specific antigens for immunodiagnosis. In the present study, recombinant protein Rv1985c from RD2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic value for tuberculosis (TB) infection among BCG-vaccinated individuals.
METHODS
T-cell response to Rv1985c was evaluated by IFN-γ ELISPOT in 56 TB patients, 20 latent TB infection (LTBI) and 30 BCG-vaccinated controls in comparison with the commercial T-SPOT. TB kit. Humoral response was evaluated by ELISA in 117 TB patients, 45 LTBI and 67 BCG-vaccinated controls, including all those who had T-cell assay, in comparison with a commercial IgG kit.
RESULTS
Rv1985c was specifically recognized by cellular and humoral responses from both TB and LTBI groups compared with healthy controls. Rv1985c IgG-ELISA achieved 52% and 62% sensitivity respectively, which outperformed the sensitivity of PATHOZYME-MYCO kit (34%) in detecting active TB (P = 0.011), whereas IFN-γ Rv1985c-ELISPOT achieved 71% and 55% sensitivity in detecting active and LTBI, respectively. Addition of Rv1985c increased sensitivities of ESAT-6, CFP-10 and ESAT-6/CFP-10 combination in detecting TB from 82.1% to 89.2% (P = 0.125), 67.9% to 87.5% (P < 0.001) and 85.7% to 92.9% (P = 0.125), respectively.
CONCLUSIONS
In conclusion, Rv1985c is a novel antigen which can be used to immunologically diagnose TB infection along with other immunodominant antigens among BCG-vaccinated population.
背景
结核分枝杆菌差异区（RD）编码的抗原构成了用于免疫诊断的特定抗原的潜在来源。在本研究中，从 RD2 克隆、表达、纯化了重组蛋白 Rv1985c，对其进行了免疫学鉴定，并研究了其在卡介苗（BCG）接种人群中对结核感染的潜在诊断价值。
方法
采用 IFN-γ ELISPOT 法检测 56 例结核病患者、20 例潜伏性结核感染（LTBI）和 30 例 BCG 接种对照者的 T 细胞反应，与商业 T-SPOT.TB 试剂盒进行比较。采用 ELISA 法检测 117 例结核病患者、45 例 LTBI 和 67 例 BCG 接种对照者的体液反应，包括所有进行细胞检测的患者，与商业 IgG 试剂盒进行比较。
结果
与健康对照组相比，Rv1985c 可被结核病和 LTBI 组的细胞和体液反应特异性识别。Rv1985c IgG-ELISA 的敏感性分别为 52%和 62%，优于 PATHOZYME-MYCO 试剂盒（34%）（P=0.011），而 IFN-γ Rv1985c-ELISPOT 的敏感性分别为 71%和 55%，用于检测活动性和 LTBI。加入 Rv1985c 可使 ESAT-6、CFP-10 和 ESAT-6/CFP-10 组合检测结核病的敏感性从 82.1%提高到 89.2%（P=0.125）、67.9%提高到 87.5%（P<0.001）和 85.7%提高到 92.9%（P=0.125）。
结论
总之，Rv1985c 是一种新的抗原，可与卡介苗接种人群中的其他免疫优势抗原一起用于免疫诊断结核感染。
Zotero 插件